• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VNDA alert in real time by email
    New Drug Application (NDA): 022192
    Company: VANDA PHARMS INC
    • Email
    • Other Important Information from FDA
    • Summary Review

    Products on NDA 022192

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    FANAPT ILOPERIDONE 1MG TABLET;ORAL Prescription AB Yes Yes
    FANAPT ILOPERIDONE 2MG TABLET;ORAL Prescription AB Yes No
    FANAPT ILOPERIDONE 4MG TABLET;ORAL Prescription AB Yes No
    FANAPT ILOPERIDONE 6MG TABLET;ORAL Prescription AB Yes No
    FANAPT ILOPERIDONE 8MG TABLET;ORAL Prescription AB Yes No
    FANAPT ILOPERIDONE 10MG TABLET;ORAL Prescription AB Yes No
    FANAPT ILOPERIDONE 12MG TABLET;ORAL Prescription AB Yes No

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 022192

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    05/06/2009 ORIG-1 Approval Type 1 - New Molecular Entity STANDARD Label (PDF)
    Letter (PDF)
    Review
    Summary Review
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022192s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022192s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022192s000TOC.cfm
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    04/02/2024 SUPPL-23 Label (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022192s023lbl.pdf
    02/23/2017 SUPPL-21 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022192s018s021lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/022192Orig1s018,s021ltr.pdf
    01/06/2017 SUPPL-20 Manufacturing (CMC)

    Label is not available on this site.

    02/23/2017 SUPPL-18 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022192s018s021lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/022192Orig1s018,s021ltr.pdf
    01/05/2016 SUPPL-17 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022192s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/022192Orig1s017ltr.pdf
    03/29/2016 SUPPL-16 Manufacturing (CMC)

    Label is not available on this site.

    05/26/2016 SUPPL-15 Efficacy-Labeling Change With Clinical Data Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022192s015lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/022192Orig1s015ltr.pdf
    03/30/2015 SUPPL-14 Manufacturing (CMC)

    Label is not available on this site.

    04/21/2014 SUPPL-13 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022192s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/022192Orig1s013ltr.pdf
    07/19/2013 SUPPL-12 Manufacturing (CMC)

    Label is not available on this site.

    05/30/2013 SUPPL-11 Manufacturing (CMC)

    Label is not available on this site.

    07/12/2013 SUPPL-10 Manufacturing (CMC)

    Label is not available on this site.

    01/27/2012 SUPPL-9 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022192s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022192s009ltr.pdf
    01/31/2013 SUPPL-7 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022192s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/022192Orig1s007ltr.pdf
    09/07/2011 SUPPL-6 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022192s005s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022192s005,s006ltr.pdf
    09/07/2011 SUPPL-5 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022192s005s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022192s005,s006ltr.pdf
    03/21/2011 SUPPL-4 Labeling Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022192s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022192s004ltr.pdf
    12/01/2010 SUPPL-2 Labeling Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022192s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022192s002ltr.pdf
    08/24/2010 SUPPL-1 Labeling Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022192s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022192s001ltr.pdf

    Labels for NDA 022192

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    04/02/2024 SUPPL-23 Efficacy Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022192s023lbl.pdf
    02/23/2017 SUPPL-21 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022192s018s021lbl.pdf
    02/23/2017 SUPPL-18 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022192s018s021lbl.pdf
    05/26/2016 SUPPL-15 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022192s015lbl.pdf
    01/05/2016 SUPPL-17 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022192s017lbl.pdf
    04/21/2014 SUPPL-13 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022192s013lbl.pdf
    01/31/2013 SUPPL-7 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022192s007lbl.pdf
    01/27/2012 SUPPL-9 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022192s009lbl.pdf
    09/07/2011 SUPPL-6 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022192s005s006lbl.pdf
    09/07/2011 SUPPL-5 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022192s005s006lbl.pdf
    03/21/2011 SUPPL-4 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022192s004lbl.pdf
    12/01/2010 SUPPL-2 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022192s002lbl.pdf
    08/24/2010 SUPPL-1 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022192s001lbl.pdf
    05/06/2009 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf

    Therapeutic Equivalents for NDA 022192

    FANAPT

    TABLET;ORAL; 1MG
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    FANAPT ILOPERIDONE 1MG TABLET;ORAL Prescription Yes AB 022192 VANDA PHARMS INC

    TABLET;ORAL; 2MG
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    FANAPT ILOPERIDONE 2MG TABLET;ORAL Prescription Yes AB 022192 VANDA PHARMS INC

    TABLET;ORAL; 4MG
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    FANAPT ILOPERIDONE 4MG TABLET;ORAL Prescription Yes AB 022192 VANDA PHARMS INC

    TABLET;ORAL; 6MG
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    FANAPT ILOPERIDONE 6MG TABLET;ORAL Prescription Yes AB 022192 VANDA PHARMS INC

    TABLET;ORAL; 8MG
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    FANAPT ILOPERIDONE 8MG TABLET;ORAL Prescription Yes AB 022192 VANDA PHARMS INC

    TABLET;ORAL; 10MG
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    FANAPT ILOPERIDONE 10MG TABLET;ORAL Prescription Yes AB 022192 VANDA PHARMS INC

    TABLET;ORAL; 12MG
    TE Code = AB

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    FANAPT ILOPERIDONE 12MG TABLET;ORAL Prescription Yes AB 022192 VANDA PHARMS INC
    Get the next $VNDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VNDA

    DatePrice TargetRatingAnalyst
    10/31/2024$18.00Buy
    H.C. Wainwright
    7/11/2024$11.00Overweight
    Cantor Fitzgerald
    2/25/2022$24.00 → $12.00Buy → Hold
    Jefferies
    More analyst ratings

    $VNDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for PONVORY issued to VANDA PHARMS INC

      Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

      6/17/24 12:07:18 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for PONVORY issued to VANDA PHARMS INC

      Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

      6/17/24 12:07:18 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for FANAPT issued to VANDA PHARMS INC

      Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

      4/3/24 4:12:36 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

      WASHINGTON, June 10, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the first dose in the first-in-human clinical trial to evaluate the safety and tolerability of VCA-894A, an antisense oligonucleotide (ASO) therapeutic, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S). VCA-894A is being developed for a patient who was first diagnosed at the age of 5 with a rare subtype of CMT disease known as CMT2S.1 CMT2S is an inherited neuromuscular disorder that progressively leads to muscle w

      6/10/25 8:00:00 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

      WASHINGTON, May 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced participation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, to be held in Scottsdale, Arizona, from May 27 through May 30, 2025. The following will be presented: May 27, 2025 Presentation Title: "Pharmacokinetic Results of Single-Dose and Multiple-Dose Bioequivalence Studies of Milsaperidone and Iloperidone Immediate-Release Oral Tablets"Poster Presentation Session: IIPoster Number: T19Presenter: Sean R. Chadwick, PhD, Clinical Development A

      5/27/25 9:00:00 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

      WASHINGTON, May 16, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the company will participate in investor meetings at the Mizuho Neuro & Ophthalmology Summit 2025 in New York City on Wednesday, May 21, 2025. About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandaph

      5/16/25 5:30:00 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care